Principal Display Panel (75 mg label)
Plavix
Product Images NDC 54868-4070
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Plavix (NDC 54868-4070). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Chemical Structure (Plavix 01)
Figure (Plavix 02)
Figure (Plavix 03)
This is a graphical representation of the cumulative event rate for cardiovascular death, myocardial infarction, and stroke over the course of 12 months of follow-up for patients taking either a placebo or Plavix with aspirin. The graph shows that Plavix with aspirin resulted in a significantly lower cumulative event rate compared to placebo with aspirin.*
Figure (Plavix 04)
This is a table of characteristics and outcomes for patients on Plavix versus placebo with respect to different diagnoses, demographic factors, and concomitant medications. The table displays the percent events for each category as well as the Hazard Ratio (95% CI).*
Figure (Plavix 05)
The text appears to be a comparison of the mortality rates of Placebo and Clopidogrel (a medication used to prevent blood clots) in patients. The data shows that out of 1845 patients who had taken Placebo, 8.1% had died while out of 1726 patients who had taken Clopidogrel, 7.5% had died. The text also includes mention of "proportional risk before reduction" and a "p-value of 0.03". The timeline of the study is also noted, which involved a total of 28 days.*
Figure (Plavix 06)
This appears to be a statistical report comparing Placebo and Clopidogrel in terms of re-infarction reduction after discharge, with data presented for up to 28 days from randomization. Both groups had a significant rate of events, with Clopidogrel appearing to have a slightly lower rate than Placebo (9.2% vs 10.1%). The report also states a proportional risk reduction of death and re-infarction (p=0.002) for Clopidogrel. There are some unclear symbols and formatting issues in the text provided, but this is the best interpretation based on the given material.*
Figure (Plavix 07)
Figure (Plavix 08)
This is a statistical table with information related to the effect of clopidogrel on different events and conditions. It includes the categorization, number of participants in each group, odds ratios, confidence intervals, and heterogeneity tests. The data suggests that clopidogrel is better than placebo in reducing proportional reduction in total events, with a p-value of 0.002. The table also includes information about Killip class, previous MI, and infarct location.*
Figure (Plavix 09)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
